[go: up one dir, main page]

MA67325B1 - Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble - Google Patents

Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Info

Publication number
MA67325B1
MA67325B1 MA67325A MA67325A MA67325B1 MA 67325 B1 MA67325 B1 MA 67325B1 MA 67325 A MA67325 A MA 67325A MA 67325 A MA67325 A MA 67325A MA 67325 B1 MA67325 B1 MA 67325B1
Authority
MA
Morocco
Prior art keywords
disorder
disease
treatment
naphthyridinone derivatives
naphthyridinone
Prior art date
Application number
MA67325A
Other languages
English (en)
Inventor
Yu GAI
Atwood Kim Cheung
Donglei Liu
Stefan Peukert
Heng GE
Xingjuan CHANG
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA67325B1 publication Critical patent/MA67325B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, A, R1 et R3 étant tels que décrits dans la description, ainsi que des compositions et des procédés d'utilisation de tels composés.
MA67325A 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble MA67325B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
CN2022128601 2022-10-31
EP22817365.4A EP4436662B1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble
PCT/IB2022/061218 WO2023094965A1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Publications (1)

Publication Number Publication Date
MA67325B1 true MA67325B1 (fr) 2025-11-28

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67325A MA67325B1 (fr) 2021-11-23 2022-11-21 Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Country Status (26)

Country Link
US (2) US12084442B2 (fr)
EP (2) EP4656240A1 (fr)
JP (1) JP2024543107A (fr)
KR (1) KR20240110040A (fr)
CN (1) CN118382623A (fr)
AR (1) AR127698A1 (fr)
AU (1) AU2022396087A1 (fr)
CA (1) CA3235682A1 (fr)
CL (1) CL2024001524A1 (fr)
CO (1) CO2024006398A2 (fr)
CR (1) CR20240216A (fr)
DK (1) DK4436662T3 (fr)
DO (1) DOP2024000096A (fr)
EC (1) ECSP24038829A (fr)
FI (1) FI4436662T3 (fr)
HR (1) HRP20251558T1 (fr)
IL (1) IL312689A (fr)
LT (1) LT4436662T (fr)
MA (1) MA67325B1 (fr)
MX (1) MX2024006176A (fr)
PE (1) PE20241328A1 (fr)
PT (1) PT4436662T (fr)
RS (1) RS67492B1 (fr)
TW (1) TW202329949A (fr)
UY (1) UY40025A (fr)
WO (1) WO2023094965A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241229A1 (fr) * 2023-05-24 2024-11-28 Novartis Ag Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CA2073856C (fr) 1990-01-24 2002-12-03 Douglas I. Buckley Analogues de glp-1 pour le traitement du diabete
EP0618803A4 (fr) 1991-12-19 1995-03-22 Southwest Found Biomed Res Polypeptide inhibant la proteine de transfert aux esters de cholesteryl, anticorps contre le polypeptide synthetique et traitements prophylactiques et therapeutiques anti-atherosclerose.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
NZ521855A (en) 2000-04-12 2004-10-29 Novartis Ag Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
AU2003292039A1 (en) 2002-11-18 2004-06-15 Novartis Ag Imidazo(1, 5a)pyridine derivatives and methods for treating aldosterone mediated diseases
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
EP1749006A2 (fr) 2004-05-28 2007-02-07 Speedel Experimenta AG Composes organiques
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (fr) 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
CN101506216A (zh) 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
JP2010513558A (ja) 2006-12-18 2010-04-30 ノバルティス アーゲー ４−イミダゾリル−１，２，３，４−テトラヒドロキノリン誘導体、およびアルドステロン／１１−ベータ−ヒドロキシラーゼ阻害剤としてのその使用
KR20090094374A (ko) 2006-12-18 2009-09-04 노파르티스 아게 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도
EP2094680A2 (fr) 2006-12-18 2009-09-02 Novartis AG Imidazols en tant qu'inhibiteurs de synthase d'aldostérone
MX2009008264A (es) 2007-03-29 2009-08-12 Novartis Ag Compuestos espiro heterociclicos.
WO2013112932A1 (fr) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Thérapies de combinaison à l'aide de bloqueurs de canaux ioniques au sodium tardifs et de bloqueurs de canaux ioniques au potassium
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019241311A1 (fr) * 2018-06-11 2019-12-19 Northeastern University Ligands sélectifs pour la modulation des canaux girk
US20240254136A1 (en) 2020-03-03 2024-08-01 Redona Therapeutics, Inc. Compounds targeting rna-binding proteins or rna-modifying proteins
WO2022074567A1 (fr) 2020-10-06 2022-04-14 Novartis Ag Compositions pharmaceutiques comprenant des dérivés de naphtyridinone et leur utilisation dans le traitement de l'arythmie

Also Published As

Publication number Publication date
US20230203032A1 (en) 2023-06-29
LT4436662T (lt) 2025-12-29
EP4656240A1 (fr) 2025-12-03
CR20240216A (es) 2024-07-01
EP4436662A1 (fr) 2024-10-02
UY40025A (es) 2023-06-15
ECSP24038829A (es) 2024-06-28
US12084442B2 (en) 2024-09-10
AU2022396087A1 (en) 2024-04-11
PE20241328A1 (es) 2024-06-26
TW202329949A (zh) 2023-08-01
KR20240110040A (ko) 2024-07-12
CA3235682A1 (fr) 2023-06-01
JP2024543107A (ja) 2024-11-19
RS67492B1 (sr) 2025-12-31
DOP2024000096A (es) 2024-06-30
CN118382623A (zh) 2024-07-23
MX2024006176A (es) 2024-06-11
AR127698A1 (es) 2024-02-21
WO2023094965A1 (fr) 2023-06-01
PT4436662T (pt) 2025-12-16
FI4436662T3 (fi) 2025-12-12
IL312689A (en) 2024-07-01
HRP20251558T1 (hr) 2026-01-16
EP4436662B1 (fr) 2025-09-17
CL2024001524A1 (es) 2024-11-08
US20250214989A1 (en) 2025-07-03
CO2024006398A2 (es) 2024-07-18
DK4436662T3 (da) 2025-12-22

Similar Documents

Publication Publication Date Title
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2024000299A (es) Compuestos antivirales.
PH12021552482A1 (en) Compounds targeting prmt5
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
PH12022551523A1 (en) Cyclic compounds and methods of using same
PH12021552513A1 (en) Pyrrole compounds
MX2022008487A (es) Degradadores de smarca2-vhl.
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
EP4316504A3 (fr) Composés
MX2021007247A (es) Derivados de rapamicina.
MX2024002409A (es) Terapias contra el cancer.
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
PH12021552953A1 (en) Tricyclic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MA67325B1 (fr) Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
JOP20210353A1 (ar) مركبات وطرق استخدامها كعوامل مضادة للجراثيم